3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
22
Immunoglobulin Light-chain Amyloidosis
4
Waldenstrom Macroglobulinemia
3
Recurrence
2
Lymphoma, T-Cell, Peripheral
2
Smoldering Multiple Myeloma
1
Sarcoma, Kaposi
1
Proteostasis Deficiencies
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Interventions
Dexamethasone
3
daratumumab
2
Lenalidomide
2
pomalidomide
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
carfilzomib
1
auricularum
1
Specimen Handling
1
Radiotherapy
1
Immunotherapy, Adoptive
1
Calcium Dobesilate
1
Bortezomib
1
Biopsy
1
2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Plasmacytoma
×
ixazomib
×
1 year
×
Clear all
No trials found.